The proposed MDRC brings together experienced and talented investigators, unique resources, and innovative techniques to develop medications for the treatment of cocaine and heroin abuse. Existing medications, primarily to treat heroin addiction, all have serious flaws. A major theme of this Center is that the addict population is heterogeneous and effective medications will most likely emerge for subgroups rather than as universal antidotes. The second major theme is the search for better methods to identify these subgroups and to screen possible medications for effectiveness prior to instituting large scale clinical trials. We will use tools as diverse as improved psychiatric screening, cue reactivity paradigms, laboratory self-administration protocols, brain imaging techniques, and staggered clinical trials. The proposed Center consists of 3 projects. Project I will develop a smoked heroin paradigm and then use it in the Residential Laboratory to evaluate both new medications for opiate addiction, e.g., depot naltrexone and methoclocinnamox, as well as improving outcome and acceptability of existing medications such as methadone and naltrexone. Project 2 will use an improved SPECT imaging technique to demonstrate the correlation between regional brain activation and different phases of cocaine withdrawal, developing markers for evaluating new medications. A promising medication, whether to treat withdrawal, craving, or act as a blocker, could be studied for its effect on the relevant brain markers. The quantitative nature of the findings could cut through the thicket of variables that confound integration of controlled clinical trials. In keeping with the theme of targeting subgroups, Projects 3 will evaluate treatment seeking cocaine (3) abusers and then use existing psychiatric medications to see whether treating specific disorders such as depression or anxiety will improve outcome and retention. Project 3, in addition, will use both a cue reaction paradigm and a novel clinical trial design to pilot test new medications for cocaine treatment. Overall, the Center has the potential to become an important resource in the search for better medications for heroin and cocaine abuse that will improve our treatment capability.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
1P50DA009236-01
Application #
2122328
Study Section
Special Emphasis Panel (SRCD (62))
Project Start
1994-09-30
Project End
1999-08-31
Budget Start
1994-09-30
Budget End
1995-08-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Cooper, Ziva D; Bedi, Gillinder; Ramesh, Divya et al. (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046-2055
Chao, Thomas; Radoncic, Vanya; Hien, Denise et al. (2018) Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend 185:23-32
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Vadhan, Nehal P; Corcoran, Cheryl M; Bedi, Gill et al. (2017) Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res 257:372-374
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Cooper, Ziva D; Johnson, Kirk W; Pavlicova, Martina et al. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21:895-903
Herrmann, Evan S; Cooper, Ziva D; Bedi, Gillinder et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233:2469-78

Showing the most recent 10 out of 129 publications